Print this article
- 04/15/2019

SEQENS: investing in the future of potent compounds

Chimica Oggi-Chemistry Today

Seqens’ mission is to bring R&D and industrial performance to our clients’ projects with a unique skill set and a broad continuum of technologies. Seqens operates 24 industrial plants and 3 R&D centers in Europe, North America and Asia. More than 300 scientists, engineers and experts develop tailor-made solutions for its customers and ensure that products are successfully transferred into production. In the pharmaceutical industry, Seqens supports its customers for the development, scale-up and manufacturing of drug substances from preclinical through to commercial phase and offers a large portfolio of APIs and proprietary products.

 

Frederic Desdouits, CDMO General Manager at Seqens, will present our new Potent capabilities at CPhI North America. By building a new potent unit that expands our potent compound production capabilities from small to commercial scale, Seqens is expanding the scope of our contract manufacturing services. CPhI NA – Wednesday 1st -15:00 PM

 

www.cdmo.seqens.com



 

Teknoscienze publisher & event organiser
viale Brianza 22, 20127
Milano – Italy
info@teknoscienze.com
Tel +39 02 26809375

 

 

Subscribe now